NZNO seeks your feedback on a PHARMAC proposal to remove all funding restrictions from all presentations of atomoxetine, and change the funded brand of atomoxetine from Strattera to a brand supplied by Generic Partners (NZ) Limited. The Generic Partners brand of atomoxetine would be listed from 1 July 2019, and the community and hospital funding restrictions on atomoxetine would be removed at the same time. There would then be a transition period, detailed below, after which Strattera would be delisted. The Generic Partners brand of atomoxetine would be awarded sole supply from 1 December 2019 until 30 June 2022, meaning that it would be the only funded brand of atomoxetine during this time.
Please send feedback to firstname.lastname@example.org by 16 JANUARY 2019